IMUNON, Inc. announced a registered direct offering of 1,939,114 shares of common stock with warrants.
The offering is priced at $3.61 per share and is expected to generate approximately $7.0 million in gross proceeds.
The transaction involves a securities purchase agreement with a healthcare-focused institutional investor.
Offering Details
1,939,114 shares of common stock with warrants priced at $3.61 per share.
Lead Placement Agent
Maxim Group LLC is the lead placement agent for the offering.
Gross Proceeds
Expected gross proceeds of approximately $7.0 million before deducting fees.
- IMUNON's fundraising through the offering will support its Phase 3 development with DNA-mediated immunotherapy.
- The pricing at-the-market under NASDAQ rules reflects investor confidence in IMUNON's clinical-stage status.
The successful pricing of the registered direct offering positions IMUNON for further advancement in its innovative treatments portfolio.